BBBridgeBio Pharma BBIO · NASDAQ
$67.94 +2.33% (+$1.55)
- Market cap
- $13.3B
- Enterprise value
- $15.1B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 19.2x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -61.8%
- Gross margin
- 93.1%
- Net margin
- -100.6%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.97
- Free float
- 85.5%
About the company
BridgeBio Pharma, Inc. is an American biotechnology company focused on the development and commercialization of innovative drugs for rare genetic diseases and cancer. Founded in 2015, the company's primary goal is to develop medicines that target the underlying genetic mechanisms causing various rare diseases. BridgeBio leverages advanced scientific technologies to identify genetic causes of diseases and then develops therapeutic options that may alleviate or even eliminate the symptoms of these conditions. The company has a portfolio of therapeutic programs in various stages of clinical trials and collaborates with other biotechnology companies and research institutions to accelerate the development of its products.
Sector
Healthcare
Industry
Biotechnology
CEO
Neil Kumar
Employees
999
Headquarters
Palo Alto
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number